-
VOLUNTARY ANNOUNCEMENT - AMEILE PHASE III STUDY MET ITS PRIMARY ENDPOINT IN THE FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER2021-02-21
-
VOLUNTARY ANNOUNCEMENT - LICENSING AGREEMENT WITH SCYNEXIS2021-02-17
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 20212021-02-03
-
PUBLICATION OF OFFERING CIRCULAR - HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED - US$600 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 20262021-01-25
-
NOTICE OF LISTING ON THE STOCK EXCHANGE OF HONG KONG LIMITED - HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED - US$600 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 20262021-01-24
-
COMPLETION OF THE ISSUE OF US$600 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 20262021-01-22
-
PROPOSED ISSUE OF US$600 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 20262021-01-08
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 20202021-01-05
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 20202020-12-03
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF“OLANZAPINE ORAL FAST DISSOLVING FILMS”2020-11-27
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 20202020-11-03
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF“SAXAGLIPTIN TABLETS”2020-10-30
